Intellia Therapeutics (NASDAQ:NTLA) Upgraded to Sell at StockNews.com

StockNews.com upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) to a sell rating in a research note issued to investors on Friday morning.

Several other research analysts have also recently issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $54.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Chardan Capital cut their price target on shares of Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating for the company in a report on Thursday, October 24th. JPMorgan Chase & Co. reduced their price objective on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Citigroup lowered their target price on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Finally, The Goldman Sachs Group dropped their target price on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.94.

Intellia Therapeutics Trading Up 4.6 %

Shares of Intellia Therapeutics stock traded up $0.73 on Friday, reaching $16.73. 2,418,301 shares of the stock were exchanged, compared to its average volume of 2,854,846. The firm has a market capitalization of $1.70 billion, a PE ratio of -3.05 and a beta of 1.81. Intellia Therapeutics has a 1-year low of $13.95 and a 1-year high of $34.87. The business has a fifty day moving average price of $19.17 and a two-hundred day moving average price of $22.22.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. The business’s revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.38) EPS. Research analysts expect that Intellia Therapeutics will post -5.21 EPS for the current year.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.20% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Blue Trust Inc. grew its position in shares of Intellia Therapeutics by 1,664.3% in the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after purchasing an additional 1,398 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after buying an additional 1,550 shares during the last quarter. Eastern Bank purchased a new stake in Intellia Therapeutics in the 3rd quarter valued at about $41,000. Values First Advisors Inc. acquired a new position in shares of Intellia Therapeutics during the 3rd quarter valued at about $54,000. Finally, First Horizon Advisors Inc. lifted its holdings in shares of Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after acquiring an additional 472 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.